Richmond Pharmacology is delighted to confirm our participation in BIO International Convention 2025 in Boston, the premier global event for biotechnology, attracting innovators and industry leaders from around the world.

With thousands of professionals expected to attend, this year’s convention will emphasize breakthroughs in therapeutic discovery, cutting-edge technologies, and global clinical collaboration.

Representing Richmond Pharmacology at BIO International Convention:

●    Dr. Jörg Täubel, Chief Executive Officer

●    Dr Lisa Campbell, Director of Regulatory Strategy

●    Stephen Wilkinson, Business Development Manager

●    Amina Senoussi, Key Account Executive

Our team is excited to connect with biotech innovators and trial sponsors to explore opportunities in:

●    Gene editing and RNA-based therapies

●    Rare and ultra-rare disease research

●    Innovative regulatory pathways

●    Bridging studies

●    Patient-centric clinical trial delivery

Whether you're advancing a ground breaking therapy or expanding into new markets, we invite you to meet us at Booth 765 in the Exhibit Hall to discover how Richmond Pharmacology can help achieve your clinical development objectives.

For meeting requests or collaboration inquiries, please contact:
📧 s.wilkinson@richmondpharmacology.com

 Learn more about the event

Latest news

How Richmond Pharmacology Supports Sponsors Navigating ICH E6 (R3)

February 5, 2026
The updated ICH E6 (R3) guideline places greater emphasis on proportionality, risk-based oversight...
Read more

Events

Clinical Trials Innovation Programme

10 - 11 February 2026
Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.
View event